Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) had Consolidated Net Income/Loss of $23.43M for the most recently reported fiscal year, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$23.43M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$23.43M |
|
|
Consolidated Net Income/Loss |
$23.43M |
-- |
|
-- |
|
-- |
|
49.84M |
|
49.84M |
|
$0.47 |
|
$0.47 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|